⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13745144 | 1.00 | — | — | |
| SCHEMBL13745145 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL10439209 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL10439273 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL10439437 | 0.97 | — | — | |
| SCHEMBL758590 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL11135283 | 0.80 | THRB (0.32) | — | |
| SCHEMBL1160224 | 0.78 | HTT (0.54) | — | |
| SCHEMBL19971070 | 0.75 | HTT (0.52) | — | |
| SCHEMBL15624617 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0369944-A1 | Substituted oxadiamino butanes | CIBA-GEIGY AG (CH) | 1990-05-23 | — | — | EP | claimed |
| WO-2020252205-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | Praxis Biotech LLC (US) | 2020-12-17 | — | — | WO | disclosed |
| US-8546419-B2 | Dual phase drug release system | THE GENERAL HOSPITAL CORPORATION (US) | 2013-10-01 | — | — | US | disclosed |
| EP-1681303-B1 | HASylated polypeptides, especially HASylated erythropoietin | FRESENIUS KABI DE GMBH (DE) | 2013-09-04 | — | — | EP | disclosed |
| US-8475765-B2 | Hydroxyalkyl starch derivatives | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2013-07-02 | — | — | US | disclosed |
| US-20120289535-A1 | DUAL PHASE DRUG RELEASE SYSTEM | THE GENERAL HOSPITAL CORPORATION (US) | 2012-11-15 | — | — | US | disclosed |
| US-8247427-B2 | Dual phase drug release system | THE GENERAL HOSPITAL CORPORATION (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120046240-A9 | Method of Producing Hydroxyalkyl Starch Derivatives | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2012-02-23 | — | — | US | disclosed |
| US-8101164-B2 | Dual phase drug release system | THE GENERAL HOSPITAL CORPORATION (US) | 2012-01-24 | — | — | US | disclosed |
| US-20120004255-A1 | DUAL PHASE DRUG RELEASE SYSTEM | THE GENERAL HOSPITAL CORPORATION (US) | 2012-01-05 | — | — | US | disclosed |
| US-7815893-B2 | Hydroxyalkyl starch derivatives | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-7790150-B2 | Dual phase drug release system | THE GENERAL HOSPITAL CORPORATION (US) | 2010-09-07 | — | — | US | disclosed |
| US-20070190018-A1 | Dual phase drug release system | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-08-16 | — | — | US | disclosed |
| EP-1667726-A2 | POLYACETAL DRUG CONJUGATES AS RELEASE SYSTEM | THE GENERAL HOSPITAL CORPORATION (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005023294-A2 | POLYACETAL DRUG CONJUGATES AS RELEASE SYSTEM | THE GENERAL HOSPITAL CORPORATION (US) | 2005-03-17 | — | — | WO | disclosed |
| CN-1171838-C | Method for isomerising allyl alcohols | �����ɷ� | 2004-10-20 | — | — | CN | disclosed |
| CN-1402699-A | Method for isomerizing allyl alcohols | BASF AG (DE) | 2003-03-12 | — | — | CN | disclosed |
| US-5169867-A | Antitumor agents, anticarcinogenic agents | CIBA-GEIGY CORPORATION (US) | 1992-12-08 | — | — | US | disclosed |
| EP-0452264-A1 | Hydroxylamine compounds | CIBA-GEIGY AG (CH) | 1991-10-16 | — | — | EP | disclosed |
| EP-0369944-A1 | Substituted oxadiamino butanes | CIBA-GEIGY AG (CH) | 1990-05-23 | — | — | EP | disclosed |